Crandon and Nicolau (2013) tested the efficacy of CAZ/AVI and ATM using the neutropenic-mouse thigh infection model, and concluded that this combination represents an attractive treatment option for infections caused by MBL-producing strains that co-produce ESBLs or AmpC. Although studies have demonstrated good in vitro activity of CAZ/AVI and ATM against MBL-producing Enterobacteriaceae (Marshall et al., 2017; Wenzler et al., 2017), clinical data are still lacking. Here, ATM is linked to infection.